A Preview Of Moleculin Biotech's Earnings
Portfolio Pulse from Benzinga Insights
Moleculin Biotech (NASDAQ:MBRX) is scheduled to release its quarterly earnings report on March 22, 2024, with an expected EPS of $-0.20. Historical data shows mixed reactions to past earnings, with the stock price often dropping post-announcement. Shares have declined 56.44% over the last year, indicating a bearish outlook among long-term investors.
March 21, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Moleculin Biotech is expected to report an EPS of $-0.20 for the upcoming quarter. Historical performance shows a tendency for the stock price to drop following earnings announcements, despite occasional EPS beats.
Given Moleculin Biotech's history of stock price declines following earnings reports, even when beating EPS estimates, and the overall 56.44% decline over the past year, it's likely that the upcoming earnings report could lead to a short-term negative impact on MBRX's stock price. The expected EPS of $-0.20 and the company's past performance suggest a cautious outlook among investors.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100